HM15275_Dosage, benefits & legal status
Also known as HM15275, LA-GLP/GIP/GCG, HM-OBCT-201
A triple agonist worth watching, with a number that is routinely quoted out of its timeframe.
What is HM15275?
Plain language first. The technical label stays, but it never stands alone.Overview
What it's used for
An investigational weekly injection for obesity that hits three metabolic receptors at once.
How does HM15275 work?
What it does in the body, and where.HM15275 activates the GLP-1, GIP and glucagon receptors together, which is the same combination retatrutide uses. What differs between triple agonists is the balance between the three.
- 01Three receptors, deliberately unbalancedThe developer describes it as rationally designed with balanced activity optimized for weight reduction and glycemic control. The ratio between the three activities is the design choice that separates one triple agonist from another, and it is not published in numbers.
- 02Glucagon is the part that burns rather than suppressesGLP-1 and GIP work largely through appetite and insulin. Adding glucagon receptor activity raises energy expenditure, which is the mechanism behind the hope that this class spares muscle while taking off fat.
- 03Long-acting through the developer's own platformThe compound carries the company's half-life extension technology, which is what makes a weekly injection possible.
- 04Where it actually standsPhase 1 is done and reported only as a poster. Phase 2 finished enrolling 267 people against a 250 target and runs 36 weeks with percent change in body weight as the primary endpoint. Until that reports, the only human efficacy number is a four-week one.

What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Obesity and overweight with a weight-related comorbidity, the phase 2 indicationtrial-protocol
- Type 2 diabetes, a separate phase 2 program the developer has announcedInvestigational
- Preserving lean mass, assessed in the phase 2 study and claimed preclinically, not demonstrated in peoplenone
The published record
Papers about HM15275 · this compound only
Searched: HM15275, LA-GLP/GIP/GCG, HM-OBCT-201.
3 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
3 registered trials · none with posted results
Furthest stage reached: Phase 2, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

At a glance
Four things to know about HM15275
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Not published
How much, and do you cycle it?
The range, and whether you take breaks.0.5 to 8 mg weekly in phase 1; the phase 2 dose levels include amounts above 8 mg and are not individually published, weekly. Not cycled in the trials Trial dose
Given weekly for the whole 36-week study period with the dose stepped up at the start, which is a ramp rather than a cycle.
How long does it stay in the body?
The half-life, and where the figure comes from.Not publishedNo figure
No measured half-life has been published. Weekly dosing in both the phase 1 and phase 2 studies implies a half-life engineered to support it, but implying is not measuring and no figure appears in anything read here.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
HM15275 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Not applicable: this is an investigational compound with no approved use
- Anyone outside a registered clinical trial, because there is no legitimate supply
- People with type 2 diabetes, who are excluded from the phase 2 obesity study
Stop and get help
- Not applicable outside a clinical trial, where the protocol and the study doctor govern
Common effects
- Mostly mild gastrointestinal effects in phase 1, as described by the developer.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is HM15275 approved?
And where the numbers on this page come from.No. HM15275 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked17 November 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
What else is like HM15275?
Others in GLP-1 agonists, side by side.If you're weighing HM15275, it's worth reading KAI-4729, Lixisenatide (Adlyxin), and MBX 4291 in the same class.
A triple agonist worth watching, with a number that is routinely quoted out of its timeframe.
- Dose
- 0.5 to 8 mg weekly in phase 1; the phase 2 dose levels include amounts above 8 mg and are not individually published
- How often
- Weekly
An experimental weekly GLP-1/GIP/glucagon triple agonist, not to be confused with retatrutide.
- Dose
- 1 up to 12 mg per week (trial doses)
- How often
- Weekly
An approved GLP-1 that lost the race and left the US market.
- Dose
- Set by the label
- How often
- Once daily
An experimental once-monthly GLP-1/GIP prodrug in its first human trial.
- Dose
- 30 mg weekly for 4 weeks, then 120 to 180 mg monthly (trial regimens)
- How often
- Weekly, then monthly (trial regimens)
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Hanmi Pharmaceutical, ObesityWeek 2025 poster P-218(2025)The developer's own phase 1 poster, which is the primary document for the dosing and the design. HM15275 is described as a novel long-acting GLP-1, GIP and glucagon triple co-agonist rationally designed with balanced activity optimized for weight reduction and glycemic control. The first-in-human study was NCT06481098, randomized, with cohorts of ten people each escalating through four dose steps: 0.5, 0.5, 2.0, 2.0 mg; 0.5, 1.0, 2.0, 4.0 mg; and 0.5, 2.0, 4.0, 8.0 mg. The poster's own conclusion is measured: weight loss observed over the short study duration suggests clinically meaningful effects and supports further investigation. It also states the phase 2 obesity study would start in the fourth quarter of 2025 as NCT07205900, with a phase 2 type 2 diabetes study planned for the first quarter of 2026.
- Third-party trial listing for NCT07205900, Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus(2026)The phase 2 design, read from a third-party listing and not from the registry. ClinicalTrials.gov was tried at source for NCT07205900 and returned only its own site shell, with empty metadata and no study record, which is what that site does for a reader that cannot run its scripts. So the design below is reported at one remove and should be read that way. HM-OBCT-201 is described as a phase 2 randomized, double-blind, placebo-controlled, multicenter, parallel group study of HM15275 over 36 weeks in adults who are obese, with a body mass index of 30 to 50, or overweight, with a body mass index of 27 to under 30 and at least one weight-related comorbidity. Type 2 diabetes is an exclusion, as are obesity from an endocrine or genetic disorder and prior obesity surgery or device therapy within the stated windows.
- BioSpectator, Hanmi completes US phase 2 enrollment for triple agonist HM15275(2026)Where enrollment landed and what the phase 1 number actually was. The developer said it completed US phase 2 enrollment with 267 patients against a 250 target, moving the registry status from recruiting to active and not recruiting, with completion expected in January 2027 and body weight change at 36 weeks as the primary endpoint alongside an assessment of lean mass. The same report gives the phase 1 figure in its own context: a maximum of 4.8 percent weight loss when 8 mg was given for four weeks, with the phase 2 study to include doses above 8 mg. It also records that phase 1 saw no serious adverse events or discontinuations, mostly mild gastrointestinal effects, and that the preclinical comparison claiming 10 percentage points more weight loss than competing triple agonists is the company's own.
Beyond these, 3 records are indexed for this compound. Browse the records
